<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025124</url>
  </required_header>
  <id_info>
    <org_study_id>304727</org_study_id>
    <nct_id>NCT05025124</nct_id>
  </id_info>
  <brief_title>Entia Liberty: Accuracy and Precision</brief_title>
  <official_title>Entia Liberty: Analytical Performance Validation - Accuracy and Precision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entia Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entia Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study forms part of Entia's clinical evidence for regulatory submission. This study&#xD;
      evaluates Entia Liberty's performance claims with venous blood compared to the gold standard&#xD;
      clinical laboratory haematology analysers. Excess blood flagged by the laboratory meeting our&#xD;
      requirements will be tested on the Entia Liberty device and have its results compared against&#xD;
      the laboratory results. Samples will also be flagged for precision testing (same blood&#xD;
      sample, split into 10 Entia Liberty samples).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To obtain the Total Error per parameter from the results of the Entia Liberty device</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain the linearity per parameter from the results of the Entia Liberty device</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain the bias per parameter from the results of the Entia Liberty device</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain the precision per parameter from the results of the Entia Liberty device</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Method comparison</arm_group_label>
    <description>400 samples to be compared directly against the reference method. This is to get the bias estimate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Precision</arm_group_label>
    <description>30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Entia Liberty</intervention_name>
    <description>Home monitoring system</description>
    <arm_group_label>Method comparison</arm_group_label>
    <arm_group_label>Precision</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        No participants will be recruited. Samples used are from excess venous bloods from the&#xD;
        Christie haematology laboratory&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Currently receiving standard of care systemic anti-cancer therapy (chemotherapy,&#xD;
             immunotherapy, endocrine and targeted therapy) for solid organ malignancy and has&#xD;
             received at least one cycle&#xD;
&#xD;
          -  Blood samples that have been stored in K2-EDTA vacutainers only&#xD;
&#xD;
          -  For Accuracy testing: Samples covering 75% of parameter ranges (Neutrophils: 0.5-7.5 x&#xD;
             109/L, Platelets: 20-450 x 109/L, Haemoglobin: 70-180 g/L), These will be determined&#xD;
             by a gold standard analyser which has been recently calibrated.&#xD;
&#xD;
          -  Reliability study: Level range per parameter. These will be determined by a gold&#xD;
             standard analyser which has been recently calibrated.&#xD;
&#xD;
          -  Neutrophils (We assume WBC to behave similarly in the same ranges) Low: 0.5-1.2 x&#xD;
             109/L (3 samples), 1.2-2 x 109/L (2 samples) Normal: 2-7 x 109/L (3-4 samples) High:&#xD;
             7-12 x 109/L (1-2 samples)&#xD;
&#xD;
          -  Platelets Low: 50-150 x 109/L (5 samples) Normal: 150-400 x 109/L (3 - 4 samples)&#xD;
             High: &gt;400 x 109/L (1-2 samples)&#xD;
&#xD;
          -  Haemoglobin Low: &lt;120 g/L (5 samples) Normal: 120-170 g/L (3 - 4 samples) High: &gt;170&#xD;
             g/L (1-2 samples)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of haematological malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

